Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Assets Average (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Assets Average for 5 consecutive years, with $376.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 17.01% year-over-year to $376.9 million, compared with a TTM value of $376.9 million through Dec 2025, up 17.01%, and an annual FY2025 reading of $353.3 million, up 9.44% over the prior year.
  • Assets Average was $376.9 million for Q4 2025 at Xeris Biopharma Holdings, up from $352.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $376.9 million in Q4 2025 and bottomed at $217.8 million in Q4 2021.
  • Average Assets Average over 5 years is $323.5 million, with a median of $325.2 million recorded in 2023.
  • The sharpest move saw Assets Average soared 48.65% in 2022, then fell 3.14% in 2025.
  • Year by year, Assets Average stood at $217.8 million in 2021, then skyrocketed by 48.65% to $323.8 million in 2022, then increased by 0.44% to $325.2 million in 2023, then decreased by 0.96% to $322.1 million in 2024, then increased by 17.01% to $376.9 million in 2025.
  • Business Quant data shows Assets Average for XERS at $376.9 million in Q4 2025, $352.4 million in Q3 2025, and $325.1 million in Q2 2025.